Intellia Therapeutics is trading 11.09% up now at $12.76 as biotechnology stocks rally alongside improving broader-market risk appetite.
- No new company-specific announcement was identified on September 17, 2026.
- The sector move follows stronger pharmaceutical and biotech demand signals, renewed M&A optimism, and a more receptive IPO environment.
- Earlier FDA priority-review news for lonvo-z remains supportive background but does not appear to be a new catalyst today.